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Abstract 
A short account is presented of the method of measuring molecular masses (M,) of pure biological samples by electrospray ionisation mass 
spectrometry. It is demonstrated that the technique yields A4, values with an effective accuracy equal to or better than 0.008% of the calculated M,, 
provided that the correct molecular structure is employed in the calculation. It is therefore recommended that this method of measuring M,‘s should 
be considered to form an essential part of all studies aimed at elucidating the molecular structure of purified biological macromolecules or for 
confirming the identity of labelled samples of such molecules. 
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1. Introduction 
The powerful technique of mass spectrometry (MS) 
requires the formation of ions from the analyte as the 
essential first step for each and every analysis. Until the 
mid-197&1980’s, MS analysis had generally been con- 
fined to volatile, neutral, low molecular weight organic 
molecules (M, I 300 Da) because the ionisation method 
employed, electron impact (EI), was only suitable for 
gases or vapours. The resulting molecular ions readily 
fragmented on account of the excess energy imparted to 
them during the ionisation process, to yield complex 
EI-MS spectra which could be interpreted in terms of 
molecular structure [l]. Then, two new ‘soft’ or low en- 
ergy ionisation methods were discovered which were 
based upon the desorption of the molecular ions of non- 
volatile analytes already present in solid or liquid matri- 
ces into the gas phase, namely fast atom bombardment 
(FAB-MS) [2] and *‘*Cf plasma desorption (PD-MS) [3] 
methods. These ionisation procedures initiated the trans- 
formation of organic mass spectrometry towards biolog- 
ical mass spectrometry since they enabled the analysis of 
non-volatile, polar and relatively large biomolecules to 
be made routinely. By 1987, one of us [4] had successfully 
ionised a protein of M, = 24,000 Da by FAB-MS and by 
1989 Roepstorff’s group in Denmark reported the ion- 
isation of a protein with M, = 45,000 Da by PD-MS [5]. 
*Corresponding author. 
However, it was the publication in 1988 of the details of 
two other new, soft ionisation techniques, electrospray 
ionisation (ESI) [6] and matrix assisted laser desorption 
ionisation (MALDI) [7], both of which could produce 
ions from very large, polar, non-volatile molecules 
(Mr = 200-300 kDa) which completed the transforma- 
tion. These initial reports generated such intense interest 
and worldwide practical activity that by 1990, Burling- 
ame et al. [8] were able to state confidently in their bi- 
annual review of mass spectrometry that, ‘MS methods 
may now be applied to virtually any structural biology 
problem’, and to predict that such methods, ‘are likely 
to become the method of choice for many biological 
studies’. 
In the present minireview, we summarise some of our 
experiences of ESI-MS gained during the last 4 years on 
commercial triple quadrupole MS instruments (VG 
BioQ). In particular, we shall focus our attention on a 
discussion of the excellent effective accuracy of A4, meas- 
urements for pure samples made using this technique and 
the implications of this for structural studies of biomol- 
ecules. For major, comprehensive reviews of the litera- 
ture on biological MS the reader is referred to the recent 
publications of Burlingame et al. [9] and Biemann [lo]. 
2. principles and practice of ESI-MS 
Electrospray ionisation (ESI) is a method of produc- 
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ing singly or multiply charged molecular ions from an 
analyte solution by spraying it (the solution) under the 
influence of a strong electrical field. The fine spray of 
solution droplets (d, = 1.2 pm) is formed by allowing the 
solution, flowing at 2-20 @mm, to emerge from the tip 
of a very fine stainless-steel (SS) capillary, which is en- 
cased in a wider bore SS capillary through which a 
stream of warm N2 gas is maintained, and from which 
it protrudes some 0.5 mm. For positive ion formation a 
voltage of + 3.5 kV is applied to the SS capillary; for 
negative ion formation the polarity of the applied voltage 
is reversed. The solvent is removed from the electrospray 
droplets by the nitrogen gas, leaving the analyte molecu- 
lar ions in the gas phase at atmospheric pressure ready 
for entry into the reduced pressure regions of the mass 
spectrometer via a pair of sampling orifices. Whilst the 
exact mechanism by which the gaseous analyte molecu- 
lar ions are formed is still not known [l I], in practice this 
simple ionisation procedure works well. The fact that 
ES1 yields stable multiply-charged molecular ions from 
solutions of macro polyelectrolytes uch as proteins is of 
crucial practical importance because it enables the use of 
relatively small spectrometers, e.g. with a maximum m/z 
range of 3,000 for singly charged ions, to measure large 
M,‘s. Thus the molecular ion of a protein of 
J$ = 100,000 Da with 100 added protons would appear 
at an m/z ratio of 100,100/100 or 1001.0. Most acidic 
protein solutions produce a series of multiply charged 
molecular ions with each ion in the series differing by + 1 
proton from adjacent ions in the series, as shown in Fig. 
la (for horse heart myoglobin). A mass spectrometer 
measures the mass-to-charge ratio (m/z) of each ion peak 
so that generally: 
where H = proton mass = 1.00794 Da and n = number 
of protons (charges) for any particular ion peak. Hence: 
M, = II ((m/z) - H) (1) 
To determine n, any two consecutive peaks differing 
by one proton in the series may be used as follows with 
reference to Fig. la. 
&+ nH 
(m/z):, = 7 and 
(m/z), = 
M, + (n + 1)H 
n+l 
so that 
(m/z)l - H 
’ = (m/z), - (mL+ (2) 
To aid interpretation, electrospray spectra are nor- 
mally transformed by routine data system procedures 
which utilise Eqs. 1 and 2 [ 121 so that all of the ion peaks 
in the original spectrum (Fig. la) originating from one 
protein are combined and presented as a single peak on 
a true M, scale, as shown in Fig. lb. The M,‘s of proteins 
measured by MS are chemical average values based on 
the average atomic weights of the elements. Mixtures of 
proteins produce even more complex spectra since each 
component gives rise to its own series of multiply 
charged peaks which do not interact [13] even though 
they may sometimes fortuitously overlap. 
In our laboratories, samples of the purified, de-salted 
protein or glycoproteins studied are generally made up 
into aqueous a~tonitr~e solutions (50150 v/v)/l~ formic 
acid, of final concentration 25-50 pmol/@. Generally, a 
10~1 aliquot of the analyte solution is injected, via a loop 
injector, into a stream of the same solvent mixture flow- 
ing at a rate of 5 @/min. The mass spectrometer is then 
routinely scanned over an appropriate m/z range, deter- 
M,+nH 
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mined ex~~entally, generally 10 s scans, and several 
scans (say I 15) are summed to obtain the final ESI-MS 
spectrum. Calibration of the m/z scale of the spectrome- 
ter is normally performed during each series of measure- 
ments using a solution of pure protein of known struc- 
ture. 
3. Validation of published macromolecular structures 
At the present time two complementary experimental 
methods are employed to determine the three dimen- 
sional molecular structure of biological ma~romol~ules, 
namely X-ray crystallography and nuclear magnetic res- 
onance spectroscopy. Unfortunately, mistakes can and 
do sometimes occur in the collection and interpretation 
of the data generated by these techniques [ 143, and in the 
dete~nation of the backbone structure (primary se- 
quence in the case of proteins) used for the initial inter- 
pretation of the former data [IS]. In addition to these 
well documented sources of error, it should be noted that 
very few samples of the biological macromolecules for 
which a 3D structure has been determined appear to 
have been assayed for purity prior to their structural 
analysis so that possible errors of interpretation of the 
experimental data due to the presence of impurities may 
also occur. The publication and dissemination of errone- 
ous molecular structures in computerised ata banks is 
a matter of serious concern since they form the basis of 
all subsequent studies on the function of the biological 
macromolecules involved and of any attempted altera- 
tion of that function by protein engineering or drug de- 
sign. Therefore, the primary aim of the present minire- 
view is to draw attention to the fact that it is now possible 
to routinely verify published macromol~ular structural 
data by ES&MS. It will now be shown that these meas- 
urements, which can be quickly made in some 2-15 mins, 
yield such accurate N,‘s that the published structures can 
either be confirmed or disproved. Further it will be de- 
monstrated that in the case of the latter finding, calcula- 
tion of the exact ma~itude of the mass difference be- 
tween the measured M, and the published M, can often 
be used to indicate the origin of the discrepancy so as to 
aid further studies aimed at resolving the conflicting 
data. Thus Table 1 below summarises our ESI-MS meas- 
urements of M, for pure samples of just three macro- 
molecules, which were chosen from data obtained for 
many hundreds of samples because two different strnc- 
tures had been published for them. 
The first protein listed in Table 1, horse heart myo- 
globin, illustrates the power of the EN-MS technique to 
detect minor errors in protein sequence data. As indi- 
cated in Fig. 1, horse heart myoglobin is used as a molec- 
ular mass standard primarily because of its commercial 
availability, purity and lack of glycosylation. When it 
was first used as a calibrant by us in 1989 the second 
calculated M, value of 16,950.5 Da given in Table 1 was 
employed because this value corresponded to the pub- 
lished sequence data given in the primary literature [16] 
which had been abstracted in the Atlas of Protein Se- 
quence and Structure [17]. However, by the autumn of 
1990 when we were engaged upon a study of abnormal 
haemoglobins, certain systematic errors were found and 
so we decided to measure the n/r, of myoglobin itself 
using a mixture of normal a- and @-globin as calibrants. 
When this was done the Mlcmeas, = 16,951.5 Da listed in 
Table 1 was obtained from a total of eight distinct meas- 
urements. Because of the vast amount of work which has 
Table 1 
The measured mean and calculated molecular masses of some biological macromolecules having two reported structures, together with the 
corresponding mass discrepancy (D) and effective accuracy (EA%) of the measurements 
Name SD. S.E.M. Molecular formula Ml(cak)a Db S.D. x 100 EA” 
@a) (Da) (Da) (Da) Mtidj (%) 
c H N 0 S 
Myoglobin (horse heart) 16,951.5 (8) 0.16 0.06 769 1,212 210 218 2 16,951,s 0.0 0.0009 0.001 
Myoglobin-H 169 1,211 210 218 2 16,950.5 1 .O 0.0009 0.007 
Retinol binding 
protein (RBP) 21,064.g (5) 0.67 0.30 926 1,410 260 285 10 21,065.6 -0.8 0.0032 0.008 
RBP-Leu 920 1,399 2.59 284 10 20,952.5 112.3 0.0032 0.542 
a-Fetoprotein (AFP) 68,799.2 (7) 3.80 1.44 3,012 4,730 796 964 40 68,800.l -0.9 0.0055 0.008 
AFP-Arg 3,006 4,718 792 963 40 68,643.g 155.3 0.0055 0.232 
S.E.M., standard error in the mass mean (M ,(,,,,$; 
recalibrated) measurements. 
S.D. is the standard deviation of the measured A4, values; n is the number of distinct (and 
“The k&~~j values were obtained from the computed molecular formuiae, derived from the structures given in the co~~~n~ng reference, in the 
text, and have been rounded to 1 decimal place. The following average atomic masses were employed: C = 12.011; H = 1.00794; N = 14.00674; 
0 = 15.9994; S = 32.066 (see [( 1991) Pure Appl. Chem., 63, 975-9901). 
h D = WCnl.W) - KW). 
“EA%=[~3xS.E.M.~+ID~]xlOO/M,,,,whereS.E.M.=~. 
n 
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been performed on the globins [ 181 we were convinced 
of the validity of their sequences and hence of their calcu- 
lated M,‘s, and therefore we concluded that the 1969 
published and 1972 abstracted sequence for myoglobin 
was incorrect. Further, consideration of the magnitude 
of this mass difference of 1 Da led us to propose that 
either one aspartic or one glutamic acid residue had been 
incorrectly identified. The first of these proposals was 
subsequently confirmed by a manual literature search 
which revealed that Lehmann’s group at Cambridge had 
re-assigned the asparagine residue at 122 to aspartic acid, 
first in 1974 [19] and again in 1975 [20] when they com- 
pared the sequences of myoglobin from horse and zebra. 
Accordingly since late 1990, whenever we have used 
myoglobin (horse heart) as a calibrant we have always 
employed the experimentally determined and calculated 
corrected sequence value of M, = 1695 1.5 Da [21]. It 
should perhaps be noted that this sequence had been 
adopted by the group which determined the 3D structure 
of horse heart myoglobin using X-ray crystallographic 
techniques [22]. Additional evidence in support of the 
correctness of our experimental mean M, value comes 
from a recent paper [23] which reports a combined enzy- 
matic hydrolysis/FAB-MS dete~ination of the se- 
quence of the relevant peptide (119-133) from horse 
heart myoglobin. 
The second protein listed, human serum retinol bind- 
ing protein (RPB), affords an example of the use of 
ESI-MS to identify major errors in published protein 
sequences, i.e. errors in the length of the primary se- 
quence. The &f, of RBP was routinely measured and, as 
shown in Table 1, was found to be 21,064.S Da. In this 
case we first compared the measured M, with that calcu- 
lated from the reported primary sequence of 182 residues 
[24] because it was employed by the Uppsala group of 
crystallographers for their 31) structural dete~ination 
[25]. As shown in Table 1, the corresponding calculated 
M, = 20,952.5 Da and hence the difference between this 
and the experimental value is 112.3 Da, indicating that 
the published protein sequence was probably lacking a 
leucine or an isoleucine residue (113.2 Da) or possibly an 
asparagine residue [114.1 Da). A comprehensive litera- 
ture search was then undertaken and this revealed that 
the Uppsala crystallographic group had later published 
[26] a refinement of their previous X-ray structure of 
RBP to 2 A resolution using a primary sequence of 183 
residues with an additional leucine residue at the C-ter- 
minal albeit without comment or reference! Clearly this 
new sequence confirms the validity of our experimental 
mean M, value listed in Table 1 and indicates that the 
most plausible of our suggestions, namely an additional 
leucine (or isoleucine), was in fact correct. 
Human ol-fetoprotein (AFP), the third illustrative ex- 
ample of a biological macromolecule with two reported 
protein structures listed in Table 1 is, in spite of its name, 
a glycoprotein. A study of the measured mean n/l: value 
obtained for the sample of AFP employed and compari- 
son with that calculated using the published structure of 
the major glycan [27] and the most recent (1991) of the 
reported structures of the protein [18] shows excellent 
agreement. However, if the mass of this glycan is added 
to the calculated mass of the first (1983) reported struc- 
ture of the protein [29] a calculated Mr = 68643.93 Da 
results, reflecting the mass difference due to the ‘missing’ 
N terminal arginine residue in this structure. Such a large 
mass difference would have been immediately apparent 
from the present ESI-MS measurements and a confident 
prediction of a missing arginine residue would have been 
possible had only this first protein structure been pub- 
lished. It should perhaps be noted that the (AFP) 
glycoprotein example presented here was chosen because 
it exists mainly as a single glycoform [30]. The majority 
of glycoproteins which we have analysed to date exist as 
complex (and variable) mixtures of different glycoforms 
the structures of which may [31] or may not [32] be 
resolved by ES-MS techniques alone. 
Thus far in this discussion of the M, data no reference 
has been made to the effective accuracy (EA%) figures 
forming the last column of Table 1. The accuracy of 
M rcmeasj achieved by ESI-MS has been stated [33] to be 
‘generally to within 0.005% of the calculated value’ when 
the correct structure is used in the calculation. However, 
it is not clear to us, or to others, if this statement was 
based upon consideration of single or repeat Mrcmeasj. 
Thus Biemann [lo] states that ‘the relatively high accu- 
racy, or more precisely speaking, the precision of the 
molecular mass measurement by ESI-MS, is chiefly the 
result of averaging individual measurements in the same 
spectrum’. In an attempt to clarify the situation, and 
since all of the mass measurements reported here were 
repeat measurements (4- to 8-fold replication) performed 
on the same or different samples, we decided to calculate 
the EA- value of the measurements. The definition of this 
measure of accuracy is given in the legend of Table 1. We 
believe that it (EA) provides a realistic error estimate for 
the method, provided n is sufficiently large, since it incor- 
porates possible scale bias and statistical error in the 
mean for the selected egree of replication, and it will be 
seen (Table 1, column 8) that for the three biomolecules 
studied the maximum value of EA is 0.008%. Therefore 
the above statement concerning the accuracy of ESI-MS 
measurements should be modified to include this value 
of EA if compa~sons are being made using the mean 
value of repeat measurements of Mr. Thus for a pure 
biomolecule of Mrccalcl = 10,000 Da the maximum experi- 
mental error associated with repeat determinations of its 
M, would be + 0.8 Da; for a pure biomolecule of 
M rtcalcf = 100,000 Da the ~ax~~u~ experimental error 
associated with repeat M~~~~~~ would be & 8.0 Da pro- 
vided horse heart myoglobin or a calibrant of equivalent 
qualities could be used. Comparison of these maximum 
error estimates of 0.008% with those of & 20% com- 
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monly encountered with current SDS-PAGE methods of 
M, determination illustrate the transformation which 
ESI-MS has brought to the accuracy of the measurement 
of this key physico-chemical property of a biomolec~e. 
In view of this we should like to recommend that in 
future, ESI-MS measurement of M, should be consid- 
ered to form an essential part of all studies aimed at 
elucidating the molecular structure of biological macro- 
molecules. In particular, since we have measured i%f, of 
a single protein crystal which had been previously used 
in X-ray crystallographic studies [34], there is no practi- 
cal reason for omitting accurate J4, measurements using 
ESI-MS on such crystalline samples in order to check the 
validity of their amino acid sequences as determined by 
classical chemical or molecular biological methods. 
To conclude this discussion of the general applicability 
of our EA measurements we would like to re-emphasise 
the fact that these were made on pure, homogenous, 
de-salted samples of the biomolecules using a carefully 
calibrated and re-calibrated quadrupole mass spectrom- 
eter. All users, and potential users, of the ESI-MS tech- 
nique need to be aware of the influence of the purity of 
their samples upon the validity of the i’& results. Thus, 
if the sample is contaminated with peptides or other 
proteins then an ES&mass spectrum can generally be 
obtained which, in many cases, can be interpreted in 
terms of the molecular components of the mixture (see 
e.g. [21-351. However, if the sample is heavily contami- 
nated with salts, or non-volatile buffers, then no ESI-MS 
spectrum can be obtained. If, on the other hand, only 
traces of salts are present in the samples, then ESI-MS 
spectra may be obtained of the ionic adducts of the pro- 
teins and of any free proteins. Unfortunately, it is some- 
what fortuitous if the corresponding molecular ion peaks 
of the adducted and non-adducted species are resolved 
[36] or not. Clearly, if they are not completely resolved 
then the measured M, will be erroneous. The solution to 
this practical problem is thus to ensure that all samples 
submitted for ES&MS analysis have been vigorously de- 
salted, a process which may be accomplished by stand- 
ard dialysis, ultrafiltration or by liquid chromatographic 
procedures. It may be of interest to note here that one 
of us [37] has found that ESI-MS is tolerant to the pres- 
ence of small amounts of PEG (and probably by analogy 
to PPG) in protein samples which had been incompletely 
purified by dialysis. Finally on the subject of sample 
purity, it should be noted that the authors of the recent 
important paper [38] reporting accurate A& measure- 
ments on samples of complex mixtures of proteins, which 
had been separated on SDS-PAGE gels, followed by 
electroelution, also emphasised the need for rigourous 
removal of salts and SDS before the ESI-MS measure- 
ments were attempted. 
Further, we should also like to draw attention to the 
ability of the method to ascertain whether commercial 
(or academic) samples of biomolecnles have been cor- 
rectly labelled. If a sample has been mislabelled then the 
mass discrepancy value D = Mrcmeasj - [M&,,cJ,ak, may 
assume any value according to the molecular structures 
of the two biomolecules involved. If D = 0 Da, then the 
ESI-MS measurements cannot assist, but in all other 
cases provided D x 100IMr(ca,c&,be, > EA, then the mass 
spectrometric method would indicate a discrepancy. Up 
to the present time we have only encountered one case 
of mislabelling [35], that of ~-ch~ot~psin 
(A& = 25,430.g Da) which had been misla~lled as 01- 
chymotrypsin (M, = 25,233.7 Da). However, cases have 
been reported by other workers [39], for example of por- 
cine /?-trypsin (M, = 23,463.6 Da) being labelled as bo- 
vine/&trypsin (M, = 23,293.31 Da). It is thus clearly nec- 
essary and now feasible using ESI-MS methods to check 
the identity of labelled samples ince the current practice 
of providing, say, a UV spectrum, an HPLC chromato- 
gram, a CZE electropherogram, amino acid analysis, 
biological activity data, enzymic rate constants, is now 
known to be insufficient o characterise a biological ma- 
terial [40]. 
The important applications of MS presented and dis- 
cussed in this minireview all stem from the ability of ES1 
to produce a series of multiply charged molecular ions. 
It remains to be seen if the experiments which are now 
underway in many laboratories, including our own, 
aimed at fra~enting these molecular ions and then 
measuring and analysing the multiply charged fragment 
ions so as to determine the amino acid sequence of large 
biomolecules, will prove successful on a routine basis. 
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